Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1989-03-17
1990-10-09
Friedman, Stanley J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
A61U 31185
Patent
active
049621270
ABSTRACT:
A method for silicon reduction with Dimercatosuccinic Acid (DMSA) is described. DMSA is administered to reduce levels of silicon in blood and tissue thereby reducing blood pressure, improving kidney function, preventing or retarding the progression of chronic renal failure, treating the accumulation of silicon in advanced kidney disease, and/or preventing the onset or improving the current status of dementia and Alzheimer's Disease.
REFERENCES:
Liang Yu-i et al., Studies on Antibilharzial Drugs VI, the Anti-dotal Effects of Sodium Dimercaptosuccinate and Bal-Glucoside Against Tartar Emetic, pp. 25-32.
J. L. Domingo et al., Development Toxicity of Subcutaneously Administered meso-2, 3-Dimercaptosuccinic Acid in Mice, Fund. Appl. Tox 11:715-722 (1988).
H. Vasken Aposhian, DMSA and DMPS-Water Soluble Antidotes for Heavy Metal Poisoning, Ann. Rev. Pharmacol. Toxicol. 23:193-215 (1983).
Deborah A. Cory-Slechta, Mobilization of Lead Over the Course of DMSA Chelation Therapy and Long-Term Efficacy, J. Pharm. Exp. Therap. 246:84 (1988).
Liang et al., Acta Physiol. Sin. 21:24-32 (1957).
Richard M. Maiorino et al., Determination and Metabolism of Dithiol-Chelating Agents: Electrolytic and Chemical Reduction of Oxidized Dithiols in Urine, Anal. Biochem. 160:217-226 (1987).
Jose L. Domingo et al., Acute Aluminum Intoxication: A Study of the Efficacy of Several Antidotal Treatments in Mice, Res. Com. Chem. Pathol. Pharm. 53:93-104 (1986).
Juan M. Llobet et al., Comparison of the Effectiveness of Several Chelators After Single Administration on the Toxicity, Excretion and Distribution of Cobalt, Arch. Toxicol. 58:278-281 (1986).
Louis R. Cantilena, Jr. et al., The Effect of Repeated Administration of Several Chelators on the Distribution and Excretion of Cadmium, Tox. Appl. Pharm. 66:361-367 (1982).
Juan M. Llobet et al., Antidotes for Zinc Intoxication in Mice, Arch. Toxicol. 61:321-323 (1988).
Hirsch Handmaker et al., Clinical Experience with .sup.99m Tc-DMSA (Dimercaptosuccinic Acid), a New Renal-Imaging Agent, J. Nucl. Med., 16:28-32 (1973).
J. C. Watkinson et al., An Evaluation of the Uptake of Technetium-99m (V) Dimercaptosuccinic Acid in Patients with Squamous Carcinoma of the Head and Neck, Clin. Otalary 12:405-411 (1987).
C. A. Hoefnagel, M.D. et al., New Radionuclide Tracers for the Diagnosis and Therapy of Medullary Thyroid Carcinoma, Clin. Nucl. Med. 13:159-165 (1988).
Kenneth P. Lyons, M.D. et al., Myocardial Infarct Imaging in Patients with Technetium-99m 2, 3 Dimercaptosuccinic Acid Superiority of Technetium-99m Pyrophosphate, Clin. Nucl. Med. 12:514-518 (1987).
Gonick Harvey C.
Khalil-Manesh Farhad
Weiler Elmar W. J.
Cedars-Sinai Medical Center
Friedman Stanley J.
LandOfFree
Method for silicon reduction with dimercaptosuccinic acid (DMSA) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for silicon reduction with dimercaptosuccinic acid (DMSA), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for silicon reduction with dimercaptosuccinic acid (DMSA) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-973840